Lin, Gigin http://orcid.org/0000-0001-7246-1058
Hsieh, Ching-Yi
Lai, Ying-Chieh
Wang, Chun-Chieh
Lin, Yenpo
Lu, Kuan-Ying
Chai, Wen-Yen
Chen, Albert P.
Yen, Tzu-Chen
Ng, Shu-Hang
Lai, Chyong-Huey
Funding for this research was provided by:
National Science and Technology Council (MOST 109-2628-B-182A-007-, MOST 110-2628-B-182A-018-, MOST 111-2628-B-182A-012-, NSTC 112-2314-B-182A-127 -MY3)
Chang Gung Medical Foundation (CLRPG3K0024, CMRPG3M0731)
Article History
Received: 17 November 2023
Accepted: 23 January 2024
First Online: 10 April 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Chang Gung Medical Foundation Institutional Review Board (CGMH IRB, No. 201702080A0, registered 1 February 2018), Taiwan Food and Drug Administration (TFDA, No. 1106805404; 110IND02017, registered 7 May 2021) and <i>ClinicalTrials.gov</i> (NCT04951921, registered 7 July 2021). The participants recruited in this trial were fully explained the study information by Dr. Gigin Lin and Dr. Chun-Chieh Wang. Informed consent was obtained from all individual participants included in this study, and the first case was started on 15 July 2021.
: Not applicable.
: Albert P Chen is a Principal Scientist of GE Healthcare Canada and does not have any fiduciary responsibility. The other authors declare no conflict of interest. Gigin Lin and Ching-Yi Hsieh analyzed and controlled the data and were not employed by or a consultant for a company in the medical industry.